153 related articles for article (PubMed ID: 12092661)
1. A phase II trial with new triptorelin sustained release formulations in prostatic carcinoma.
Minkov NK; Zozikov BI; Yaneva Z; Uldry PA
Int Urol Nephrol; 2001; 33(2):379-83. PubMed ID: 12092661
[TBL] [Abstract][Full Text] [Related]
2. Triptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer: an open-label, non-comparative, multicentre, phase III study.
Lundström EA; Rencken RK; van Wyk JH; Coetzee LJ; Bahlmann JC; Reif S; Strasheim EA; Bigalke MC; Pontin AR; Goedhals L; Steyn DG; Heyns CF; Aldera LA; Mackenzie TM; Purcea D; Grosgurin PY; Porchet HC
Clin Drug Investig; 2009; 29(12):757-65. PubMed ID: 19888782
[TBL] [Abstract][Full Text] [Related]
3. Triptorelin embonate (6-month formulation).
Keating GM
Drugs; 2010 Feb; 70(3):347-53. PubMed ID: 20166771
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer.
Heyns CF; Simonin MP; Grosgurin P; Schall R; Porchet HC;
BJU Int; 2003 Aug; 92(3):226-31. PubMed ID: 12887472
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic/pharmacodynamic model of the testosterone effects of triptorelin administered in sustained release formulations in patients with prostate cancer.
Romero E; Vélez de Mendizabal N; Cendrós JM; Peraire C; Bascompta E; Obach R; Trocóniz IF
J Pharmacol Exp Ther; 2012 Sep; 342(3):788-98. PubMed ID: 22691297
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Testosterone Suppression with Sustained-Release Triptorelin in Advanced Prostate Cancer.
Breul J; Lundström E; Purcea D; Venetz WP; Cabri P; Dutailly P; Goldfischer ER
Adv Ther; 2017 Feb; 34(2):513-523. PubMed ID: 28028737
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic equivalence of a decapeptyl 3-month SR formulation with the 28-day SR formulation in patients with advanced prostate cancer.
Teillac P; Heyns CF; Kaisary AV; Bouchot O; Blumberg J
Horm Res; 2004; 62(5):252-8. PubMed ID: 15499224
[TBL] [Abstract][Full Text] [Related]
8. Triptorelin in the management of prostate cancer.
Ploussard G; Mongiat-Artus P
Future Oncol; 2013 Jan; 9(1):93-102. PubMed ID: 23252566
[TBL] [Abstract][Full Text] [Related]
9. Three-month sustained-release form of triptorelin in patients with advanced prostatic adenocarcinoma: results of an open pharmacodynamic and pharmacokinetic multicenter study.
Bouchot O; Soret JY; Jacqmin D; Lahlou N; Roger M; Blumberg J
Horm Res; 1998; 50(2):89-93. PubMed ID: 9701702
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy and safety of long-acting gonadotropin-releasing hormone analogue in the treatment for metastatic prostate cancer].
Li NC; Song Y; Jiang HW; Ding Q; Gan WD; Guo HQ; Sun ZY; Hu ZQ; Ye ZQ; Wei Q; Na YQ
Zhonghua Wai Ke Za Zhi; 2008 Nov; 46(21):1653-7. PubMed ID: 19094763
[TBL] [Abstract][Full Text] [Related]
11. An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer.
Merseburger AS; Hupe MC
Adv Ther; 2016 Jul; 33(7):1072-93. PubMed ID: 27246172
[TBL] [Abstract][Full Text] [Related]
12. [Tolerance and clinical and biological responses during the first 6 months of treatment with 1-month sustained release LHRH agonists leuprolerin and triptolerin in patients with metastatic prostate cancer].
Abbou CC; Lucas C; Leblanc V
Prog Urol; 1997 Dec; 7(6):984-95. PubMed ID: 9490144
[TBL] [Abstract][Full Text] [Related]
13. In vivo biocompatibility, sustained-release and stability of triptorelin formulations based on a liquid, degradable polymer.
Asmus LR; Tille JC; Kaufmann B; Melander L; Weiss T; Vessman K; Koechling W; Schwach G; Gurny R; Möller M
J Control Release; 2013 Feb; 165(3):199-206. PubMed ID: 23220105
[TBL] [Abstract][Full Text] [Related]
14. Eligard: leuprolide acetate in a novel sustained-release delivery system.
Sartor O
Urology; 2003 Feb; 61(2 Suppl 1):25-31. PubMed ID: 12667884
[TBL] [Abstract][Full Text] [Related]
15. [Effectiveness and tolerance of 1 dosage forms (subcutaneous and intramuscular) of decapeptyl depot in patients with advanced prostate carcinoma].
Klippel KF; Winkler CJ; Jocham D; Rübben H; Möser B; Gulati A
Urologe A; 1999 May; 38(3):270-5. PubMed ID: 10407987
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer.
Martínez-Piñeiro L; Schalken JA; Cabri P; Maisonobe P; de la Taille A;
BJU Int; 2014 Oct; 114(4):608-16. PubMed ID: 24806330
[TBL] [Abstract][Full Text] [Related]
17. Open, multi-center, phase IV study to assess the efficacy and tolerability of triptorelin in Taiwanese patients with advanced prostate cancer.
Kao CC; Chang YH; Wu T; Sun GH; Yu DS; Chang SY; Cha TL
J Chin Med Assoc; 2012 Jun; 75(6):255-61. PubMed ID: 22721619
[TBL] [Abstract][Full Text] [Related]
18. [Multicentre randomized trial comparing triptorelin medical castration versus surgical castration in the treatment of locally advanced or metastatic prostate cancer].
Botto H; Rouprêt M; Mathieu F; Richard F
Prog Urol; 2007 Apr; 17(2):235-9. PubMed ID: 17489325
[TBL] [Abstract][Full Text] [Related]
19. Single processing step toward injectable sustained-release formulations of Triptorelin based on a novel degradable semi-solid polymer.
Asmus LR; Kaufmann B; Melander L; Weiss T; Schwach G; Gurny R; Möller M
Eur J Pharm Biopharm; 2012 Aug; 81(3):591-9. PubMed ID: 22561956
[TBL] [Abstract][Full Text] [Related]
20. Luteinizing Hormone-Releasing Hormone Agonists are Superior to Subcapsular Orchiectomy in Lowering Testosterone Levels of Men with Prostate Cancer: Results from a Randomized Clinical Trial.
Østergren PB; Kistorp C; Fode M; Henderson J; Bennedbæk FN; Faber J; Sønksen J
J Urol; 2017 Jun; 197(6):1441-1447. PubMed ID: 27939836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]